With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

The only ocular movements possible were 5 to 10 ... and failed to exert any extrathyroidal influence on the myasthenia gravis. From the hundred and twentieth to the hundred and seventieth ...

Q4 and is likely to become significantly profitable and cash flow positive in 2025. Read my analysis on ARGX stock here.

Myasthenia gravis management requires that eye care clinicians understand ocular manifestations and provide follow-up care.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy.